


pirtobrutinib BTK

oral, reversible BTK inhibitor
approved for R/R MCL, in Ph. II/III for CLL/SLL, NHL
activity against Cys^{C481} BTK mutants
FDA approval, January 27, 2023


REDX, ALDERLY PARK, UK (LOXO/LILLY)



elacestrant estrogen receptor (ER)

oral, non-steroidal SERD/SERM
approved for ER+, HER2-, mESR1 adv./metastatic BC
degrades ER alpha in dose-dependent manner
FDA approval, January 27, 2023


EISAI, TOKYO, JP (STEMLINE/MENARINI)



MK-8189 PDE10A

oral PDE10A inhibitor
Ph. IIb for schizophrenia
from fragment screen + SBDD
J. Med. Chem., January 10, 2023


MERCK, WEST POINT, PA



bexotegast $\alpha\beta6/\alpha\beta1$

oral, dual-selective $\alpha\beta6$ - $\alpha\beta1$ integrin inhibitor
in Ph. II for IPF + PSC
related to reported integrin inhibitors
Press release, January 22, 2023


PLIANT THERAPEUTICS, SAN FRANCISCO, CA



BDM2 LEDGF-IN

oral HIV-1 IN-LEDGF/p75 allosteric inhibitor
Ph. I for FIH safety
from cell screen of INLAI library
BioRxiv, January 28, 2022


BIODIM, ROMAINVILLE, FR



GB0139 galectin-3

inhaled galectin-3 inhibitor
Ph. II for IPF + Ph. Ib/Ila for COVID-19 pneumonitis
synthetic galactoside derivative
medRxiv, January 10, 2023


GALECTO, INC., COPENHAGEN, DE



saridegib SMO

oral SMO inhibitor
Ph. III for Gorlin syndrome
from SAR of in-house library hit
Press release, January 27, 2023

INFINITY PHARM., CAMBRIDGE, MA (SOL-GEL)




baxdrostat aldosterone synthase

oral aldosterone synthase (CYP11B2) inhibitor
Ph. I/II for HTN, CKD, primary aldosteronism
from in-house screen of aldosterone synthase inhibitors

Press release, January 9, 2023


ROCHE, BASEL, CH (CINCOR/ASTRAZENECA)



PF-6870961 GHSR1a

GHSR1a inverse agonist
(metabolite of oral molecule)
Ph. Ia for heavy alcohol drinking
major hydroxy metabolite of PF-5190457
JPET, January 11, 2023

NIDA/NIAAA, NIH (PFIZER)



JNJ-65234637 BCL6

oral BCL6 BTB inhibitor
promising in vitro safety + in vivo oral PK data
from virtual screen + SBDD
ACS Med. Chem. Lett., January 12, 2023

OICR, TORONTO, CA (JANSSEN)